Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Precision Biotics Market to Grow from USD 4.91 Billion in 2026 to USD 9.26 Billion by 2031, at a CAGR of 13.5% — MarketsandMarkets™

globenewswire.com
PG Procter & Gamble is mentioned as a key player in the growing precision biotics market. The article does not provide specific details on their performance or outlook within this segment, making the sentiment neutral. SEED Seed Health, Inc. is recognized as a key participant in the precision biotics market, which is forecasted to grow considerably. The article lacks specific information regarding Seed Health's individual performance or outlook, resulting in a neutral sentiment.

Precision Biotics Market to Grow from USD 4.91 Billion in 2026 to USD 9.26 Billion by 2031, at a CAGR of 13.5% — MarketsandMarkets™ Delray Beach, FL, Oct. 14, 2026 (GLOBE NEWSWIRE) -- MarketsandMarkets™ projects the global precision biotics market to grow from USD 4.91 billion in 2026 to USD 9.26 billion by 2031, at a CAGR of 13.5%. Growth is driven by advances in microbiome science, increasing demand for personalized nutrition, growing awareness of gut health, rising preference for scientifically validated health products, and expanding applications across dietary supplements, functional foods, medical nutrition, and cosmetics. Asia Pacific is expected to be the fastest-growing region, while next-generation probiotics (NGPs) are projected to be the fastest-growing type segment.

Get PDF Brochure — Market Data & Segmentation:

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=110337959

Key Market Highlights

• Market size, 2026: USD 4.91 billion

• Market forecast, 2031: USD 9.26 billion

• Growth rate: CAGR of 13.5% (2026–2031)

• Fastest-growing region: Asia Pacific

• Fastest-growing type segment: Next-generation Probiotics (NGPs)

• Fastest-growing end-use industry: Cosmetics

• Report scope: 300 market data tables, 45 figures, 300 pages

• Key players: BioGaia (Sweden), Novonesis Group (Denmark), Procter & Gamble (US), Unilever (UK), dsm-firmenich (Switzerland), Metagenics, LLC (US), Yakult Honsha Co., Ltd. (Japan), Danone (France), KANEKA CORPORATION (Japan), Symrise (Germany) – Probi, Jarrow Formulas, Inc. (US), Pendulum (US), thegoodbug (India), Seed Health, Inc. (US), and Infinant Health Inc. (US)

Why This Market Matters

Growing scientific understanding of the gut and broader human microbiome is transforming the development of health and nutrition products. Precision biotics are designed to deliver targeted, scientifically supported benefits across areas such as digestive health, immune health, metabolic health, cognitive health, and healthy aging.

The increasing consumer preference for personalized and clinically validated solutions is encouraging companies to move beyond conventional probiotics toward more targeted formulations. Advances in microbiome sequencing, multi-omics, artificial intelligence, and clinical research are enabling the development of products designed around specific strains, mechanisms, and health outcomes.

Market Overview

The precision biotics market is expanding as microbiome science becomes increasingly integrated into personalized healthcare and nutrition. Companies are investing in advanced research to understand host-microbiome interactions and develop more targeted probiotic, synbiotic, postbiotic, and next-generation probiotic solutions.

Growing awareness of the relationship between microbiome health and overall well-being is also expanding applications beyond traditional digestive health. Precision biotics are increasingly being explored for metabolic health, immune function, women's health, cognitive wellness, healthy aging, and skin health.

Collaboration between biotechnology companies, healthcare organizations, nutrition companies, and research institutions is further accelerating product development and commercialization.

Analyst Perspective

Precision biotics represent a shift from broad-spectrum microbiome solutions toward targeted, evidence-based approaches. As microbiome research advances, the ability to identify specific strains, mechanisms, and host responses is expected to create new opportunities across nutrition, healthcare, functional foods, and beauty.

Future market growth will increasingly depend on clinical validation, personalized formulations, microbiome data, and technologies that can translate scientific discoveries into commercially scalable products.

Segment Analysis

By type, Next-generation Probiotics (NGPs) are projected to be the fastest-growing segment through 2031. Their ability to provide strain-specific and mechanism-based benefits is attracting growing interest as microbiomics and clinical research advance. Increasing investment in microbiome therapeutics and personalized healthcare is supporting the adoption of NGP-based solutions across metabolic, gastrointestinal, immunology, and women's health applications.

By end-use industry, Cosmetics are expected to register the fastest growth during the forecast period. Increasing consumer interest in skin microbiome health, clean-label formulations, and personalized beauty products is creating new opportunities for precision biotics. Their applications include products targeting acne, eczema, skin sensitivity, skin barrier restoration, and healthy aging.

Regional Analysis

Asia Pacific is projected to be the fastest-growing region in the precision biotics market during the forecast period. Increasing awareness of gut health, growing adoption of personalized nutrition, advances in microbiome research, and rising demand for clinically validated probiotic products are supporting regional expansion.

Growing disposable incomes, urbanization, expansion of the dietary supplements and functional foods industries, improvements in healthcare infrastructure, and increasing penetration of online retail channels are further contributing to the adoption of precision biotics across the region.

Speak to Our Analyst — Get Custom Insights:

https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=110337959

Key Industry Trends

• Growing investment in microbiome sequencing, multi-omics, and AI is accelerating precision biotics development.

• Personalized nutrition is increasing demand for targeted microbiome-based solutions.

• Next-generation probiotics are gaining momentum due to their strain-specific and mechanism-based potential.

• Precision biotics are expanding beyond digestive health into metabolic, immune, cognitive, women's, and skin health.

• Microbiome-focused cosmetics are creating new opportunities for precision biotics in the beauty industry.

• Clinical validation and evidence-based product positioning are becoming increasingly important for market adoption.

Competitive Landscape

Leading companies operating in the Precision Biotics Market include BioGaia (Sweden), Novonesis Group (Denmark), Procter & Gamble (US), Unilever (UK), dsm-firmenich (Switzerland), Metagenics, LLC (US), Yakult Honsha Co., Ltd. (Japan), Danone (France), KANEKA CORPORATION (Japan), Symrise (Germany) – Probi, Jarrow Formulas, Inc. (US), Pendulum (US), thegoodbug (India), Seed Health, Inc. (US), and Infinant Health Inc. (US).

Related Reports